Slide 1: Group Presentation
GROUP PRESENTATION
Slide 2: Who we are
SOPHARMA GROUP PRESENTATION Who we are
Slide 3: Sopharma Group in brief
3 WHO WE ARE Sopharma Group in brief More than 80 years 39 subsidiaries, 7 joint- tradition and a modern ventures and 2 associate approach to the production companies in 7 countries of medicines Strong presence in Leading, vertically- Southern and Eastern integrated Bulgarian Europe manufact
Slide 4: Sopharma Pharmaceuticals
4 SOPHARMA GROUP STRUCTURE Sopharma Pharmaceuticals Bulgarian based mother company, pharmaceutical producer Pharmaceutical Wholesale and API production Non-pharma activities production distribution Farming of medicinal Self-developed products Pre-wholesaling, Medical supplies, plants from herbal ori
Slide 5: 2016 Financial Overview
5 SOPHARMA CORPORATE PRESENTATION 2016 FINANCIAL OVERVIEW
Slide 6: Key Financial Highlights
2016 CONSOLIDATED FINANCIAL INFORMATION 6 Key Financial Highlights Sopharma Group in Revenue from sales increased to BGN 877 million BGN 2016 2015 Change million in 2016 vs. BGN 875 million 2015 Revenue 877 875 0.2% EBITDA increased by 17.4% in 2016 vs. 2015 EBITDA 74 63 17.4% driven by an optim
Slide 7: Sales revenue breakdown
7 2016 CONSOLIDATED FINANCIAL INFORMATION Sales revenue breakdown Revenue breakdown by segments in 2016 Revenue breakdown by geographic region in 2016 2% Sales of Bulgaria 26% finished products 25% Europe Distribution of goods 73% Other countries 74% Sales of finished products decreased by 8% in 2
Slide 8: Leverage Net debt/EBITDA
8 2016 CONSOLIDATED FINANCIAL INFORMATION Leverage Net debt/EBITDA Net debt decreased by BGN 17 million 2010 2011 2012 2013 2014 2015 2016 to BGN 206 million Net debt/ Long-term loans BGN 29 million EBITDA 2.1x 2.8x 3.8x 3.1x 3.7x 3.6x 2.8x Main reason for the short-term 4 exposure is the lead
Slide 9: Shareholder structure
CAPITAL MARKETS POSITION 9 Shareholder structure Donev Investments • Listed on the Bulgarian and Warsaw stock 3.91% Holding AD exchanges – 3JR/SPH 23.75% 24.78% Telekomplekt Invest AD Romfarm Company • Capital 134 797 899 shares EOOD ZUPF Alianz Bulgaria • 10.05.2016 closing price 3.905 BGN (BSE – S
Slide 10: Dividend policy
CAPITAL MARKETS POSITION 10 Dividend policy Dividend per share in BGN Dividend payout ratio 2016 2016 2010 2011 2012 2013 2014 2015 2010 2011 2012 2013 2014 2015 proposal proposal no no Sopharma AD 0.085 0.07 0.07 0.07 0.07 0.10 Sopharma AD 28% 23% 23% 27% 37% 36% dividend dividend Sopharma Sopharma
Slide 11: Plans and Financial Outlook 2017
11 SOPHARMA CORPORATE PRESENTATION PLANS AND FINANCIAL OUTLOOK 2017
Slide 12: On the lookout for opportunities
12 LOOKING AHEAD ON THE LOOKOUT FOR OPPORTUNITIES Bulgaria – acquisition of a local pharmacy chain Serbia – pending acquisition of a regional distributor Moldova – acquisition of a controlling stake in a local distributor Consolidation - mergers of subsidiaries Unipharm AD and Medica AD Ta
Slide 13: 2017 Guidance
LOOKING AHEAD 13 2017 GUIDANCE Expected growth of finished CAPEX – construction of a new products sales due to lyophilic plant to increase stabilization in Russia and production, investments within Ukraine markets depreciation levels Growth of goods sales mainly as M & A – Unipharm AD tender
Slide 14: Thank you for your time and attention!
SOPHARMA CORPORATE PRESENTATION Thank you for your time and attention! Boris Borisov Financial Director e-mail: boris@sopharma.bg